Finance

Lists
Q2 2026 earnings • released • EPS beat +77.38% • Revenue beat +11.19%
See results
BIIB:NASDAQ
Biogen Inc
$202.95
-2.40%
(-4.98) 1D
Jul 31, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BIIB...
Open
$207.51
High
$208.05
Low
$202.57
Mkt. cap
29.96B
Avg. vol.
1.45M
Volume
1.00
P/E ratio
35.94
52-wk high
$219.72
52-wk low
$124.56
EPS
$5.65
Beta
0.16
Shares outstanding
147.75M
No. of employees
8K
Open
$207.51
High
$208.05
Low
$202.57
Mkt. cap
29.96B
Avg. vol.
1.45M
Volume
1.00
P/E ratio
35.94
52-wk high
$219.72
52-wk low
$124.56
EPS
$5.65
Beta
0.16
Shares outstanding
147.75M
No. of employees
8K
News stories
From sources across the web
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com
Analyst ratings
Based on 28 analysts giving stock ratings to BIIB in the past 3 months
Buy
Buy
18
Hold
9
Sell
1
12-month forecast
Based on 28 Wall Street analysts offering 12 month price targets for BIIB in the last 3 months.
Highest
Current $202.95
$300.00 (+47.82%)
Average
$231.83 (+14.23%)
Lowest
$157.00 (-22.64%)
Analyst
Recommendation
Action
Price target
Projected
Date
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$242.00
+19.2%
08/02/2026
Chris Schott
J.P. Morgan
Hold
Maintained
$210.00
+3.5%
07/30/2026
Andrew Tsai
Jefferies
Buy
Maintained
$255.00
+25.6%
07/30/2026
Andrew Fein
H.C. Wainwright
Buy
Reiterated
$251.00
+23.7%
07/30/2026
Danielle Brill
Truist Financial
Buy
Reiterated
$235.00
+15.8%
07/31/2026
Michael Yee
UBS
Buy
Maintained
$240.00
+18.3%
07/30/2026
Evan Seigerman
BMO Capital
Hold
Reiterated
$208.00
+2.5%
07/30/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
$250.00
+23.2%
07/30/2026
Brian Abrahams
RBC Capital
Buy
Reiterated
$240.00
+18.3%
07/29/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
$248.00
+22.2%
07/30/2026
Geoff Meacham
Citi
Hold
Maintained
$200.00
-1.5%
07/29/2026
Phil Nadeau
TD Cowen
Buy
Reiterated
$225.00
+10.9%
07/30/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
$231.00
+13.8%
07/30/2026
Ami Fadia
Needham
Buy
Maintained
$256.00
+26.1%
07/29/2026
Myles Minter
William Blair
Buy
Maintained
-
-
07/29/2026
Laura Chico
Wedbush
Hold
Reiterated
$215.00
+5.9%
07/31/2026
Jason Zemansky
Bank of America Securities
Hold
Reiterated
$219.00
+7.9%
07/29/2026
Emily Field
Barclays
Hold
Reiterated
$200.00
-1.5%
07/29/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$225.00
+10.9%
07/28/2026
Jay Olson
Oppenheimer
Buy
Maintained
$300.00
+47.8%
07/23/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$280.00
+38%
07/21/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$250.00
+23.2%
07/13/2026
Thomas Shrader
BTIG
Hold
Maintained
-
-
07/13/2026
Jasper Hellweg
Argus Research
Hold
Maintained
-
-
07/10/2026
Morten Herholdt
HSBC
Sell
Maintained
$157.00
-22.6%
07/06/2026
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
$237.00
+16.8%
07/01/2026
Eric Schmidt FCA
Cantor Fitzgerald
Buy
Initiated
$206.00
+1.5%
06/22/2026
Salim Syed
Mizuho Securities
Buy
Reiterated
$221.00
+8.9%
06/12/2026
Umer Raffat
Evercore ISI
Buy
Initiated
-
-
05/15/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Upgraded
$245.00
+20.7%
05/01/2026
William Pickering
Bernstein
Hold
Maintained
$201.00
-1%
02/06/2026
Last report
Jul 29, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$3.60 / $2.03
+77.38%beat
Revenue / Est. (USD)
2.74B / 2.46B
+11.19%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.53B
2.28B
2.48B
2.74B
Cost of goods sold
508.60M
443.40M
610.20M
611.60M
Cost of revenue
508.60M
443.40M
610.20M
611.60M
Research and development expenses
431.80M
477.10M
482.20M
492.10M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
592.80M
685.20M
607.30M
709.70M
Operating expense
1.25B
1.36B
1.30B
1.44B
Total operating expenses
1.76B
1.81B
1.91B
2.05B
Operating income
778.60M
471.60M
567.40M
685.60M
Other non operating income
15.80M
17.40M
-1.10M
3.00M
EBT including unusual items
557.30M
-56.00M
377.70M
132.40M
EBT excluding unusual items
748.30M
447.00M
530.10M
625.10M
Income tax expense
90.80M
-7.10M
58.20M
34.90M
Effective tax rate
16.29%
12.68%
15.41%
26.36%
Other operating expenses
87.20M
69.90M
74.20M
68.80M
Net income
466.50M
-48.90M
319.50M
97.50M
Net profit margin
18.40%
-2.15%
12.89%
3.56%
Earnings per share
4.81
1.99
3.57
3.60
Interest and investment income
31.60M
37.20M
37.90M
25.30M
Interest expense
-67.40M
-67.50M
-67.60M
-82.30M
Net interest expenses
-35.80M
-30.30M
-29.70M
-57.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
980.80M
671.80M
771.80M
921.70M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps